# Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

> **NCT06035679** · NA · RECRUITING · sponsor: **Youzhi Zhu** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** Pyrotinib and Trastuzumab

## Key facts

- **NCT ID:** NCT06035679
- **Lead sponsor:** Youzhi Zhu
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035679, "Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06035679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*